Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
August 24, 2023
-
REGULATORY Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
August 24, 2023
-
REGULATORY Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
-
REGULATORY Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
August 24, 2023
-
REGULATORY Japan Approves Enhertu’s NSCLC Use, More Label Expansions
August 24, 2023
-
REGULATORY Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
August 23, 2023
-
REGULATORY Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
August 23, 2023
-
REGULATORY Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
August 22, 2023
-
REGULATORY MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
August 21, 2023
-
BUSINESS Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
-
BUSINESS Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
August 17, 2023
-
REGULATORY Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
August 16, 2023
-
BUSINESS Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
August 14, 2023
-
REGULATORY Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
August 10, 2023
-
REGULATORY Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
August 9, 2023
-
BUSINESS Astellas Puts Up US$50 Million for CAR-T Player Poseida
August 9, 2023
-
REGULATORY Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
August 8, 2023
-
BUSINESS Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
August 8, 2023
-
REGULATORY MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
August 8, 2023
-
COMMENTARY Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
August 7, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…